Oligonucleotide Therapeutics Industry Research Report 2023

Oligonucleotide Therapeutics Industry Research Report 2023


Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Highlights

The global Oligonucleotide Therapeutics market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

Product Type Insights

Global markets are presented by Oligonucleotide Therapeutics type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Oligonucleotide Therapeutics are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Oligonucleotide Therapeutics segment by Type

Antisense Oligonucleotide
Aptamer
Other

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Oligonucleotide Therapeutics market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Oligonucleotide Therapeutics market.
Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases
ATTR
Hepatic VOD
Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Oligonucleotide Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Oligonucleotide Therapeutics industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oligonucleotide Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Oligonucleotide Therapeutics by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
2.3 Oligonucleotide Therapeutics by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Neuromuscular Diseases
2.3.3 ATTR
2.3.4 Hepatic VOD
2.3.5 Other
2.4 Assumptions and Limitations
3 Oligonucleotide Therapeutics Breakdown Data by Type
3.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2018-2023)
3.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2023-2028)
4 Oligonucleotide Therapeutics Breakdown Data by Application
4.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2018-2023)
4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Oligonucleotide Therapeutics Market Perspective (2018-2029)
5.2 Global Oligonucleotide Therapeutics Growth Trends by Region
5.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2018-2023)
5.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2024-2029)
5.3 Oligonucleotide Therapeutics Market Dynamics
5.3.1 Oligonucleotide Therapeutics Industry Trends
5.3.2 Oligonucleotide Therapeutics Market Drivers
5.3.3 Oligonucleotide Therapeutics Market Challenges
5.3.4 Oligonucleotide Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Oligonucleotide Therapeutics Players by Revenue
6.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2018-2023)
6.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2018-2023)
6.2 Global Oligonucleotide Therapeutics Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Oligonucleotide Therapeutics Head office and Area Served
6.4 Global Oligonucleotide Therapeutics Players, Product Type & Application
6.5 Global Oligonucleotide Therapeutics Players, Date of Enter into This Industry
6.6 Global Oligonucleotide Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Oligonucleotide Therapeutics Market Size (2018-2029)
7.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Oligonucleotide Therapeutics Market Size by Country (2018-2023)
7.4 North America Oligonucleotide Therapeutics Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Oligonucleotide Therapeutics Market Size (2018-2029)
8.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Oligonucleotide Therapeutics Market Size by Country (2018-2023)
8.4 Europe Oligonucleotide Therapeutics Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2018-2029)
9.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2018-2023)
9.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Oligonucleotide Therapeutics Market Size (2018-2029)
10.2 Latin America Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Oligonucleotide Therapeutics Market Size by Country (2018-2023)
10.4 Latin America Oligonucleotide Therapeutics Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2018-2029)
11.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2018-2023)
11.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide Therapeutics Introduction
11.1.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Detail
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide Therapeutics Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Detail
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide Therapeutics Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Detail
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide Therapeutics Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022)
11.8.5 Akcea Therapeutics Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Oligonucleotide Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2018-2023)
Table 7. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2024-2029)
Table 9. Global Oligonucleotide Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2018-2023)
Table 11. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2024-2029)
Table 13. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Oligonucleotide Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Oligonucleotide Therapeutics Market Share by Region (2018-2023)
Table 16. Global Oligonucleotide Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Oligonucleotide Therapeutics Market Share by Region (2024-2029)
Table 18. Oligonucleotide Therapeutics Market Trends
Table 19. Oligonucleotide Therapeutics Market Drivers
Table 20. Oligonucleotide Therapeutics Market Challenges
Table 21. Oligonucleotide Therapeutics Market Restraints
Table 22. Global Top Oligonucleotide Therapeutics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Oligonucleotide Therapeutics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Oligonucleotide Therapeutics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Oligonucleotide Therapeutics, Headquarters and Area Served
Table 26. Global Oligonucleotide Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Oligonucleotide Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Oligonucleotide Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Oligonucleotide Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Oligonucleotide Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Oligonucleotide Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Oligonucleotide Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Oligonucleotide Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 45. Biogen Company Detail
Table 46. Biogen Business Overview
Table 47. Biogen Oligonucleotide Therapeutics Product
Table 48. Biogen Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Biogen Recent Development
Table 50. Sarepta Therapeutics Company Detail
Table 51. Sarepta Therapeutics Business Overview
Table 52. Sarepta Therapeutics Oligonucleotide Therapeutics Product
Table 53. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Sarepta Therapeutics Recent Development
Table 55. Jazz Pharmaceuticals Company Detail
Table 56. Jazz Pharmaceuticals Business Overview
Table 57. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
Table 58. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Jazz Pharmaceuticals Recent Development
Table 60. Bausch & Lomb Company Detail
Table 61. Bausch & Lomb Business Overview
Table 62. Bausch & Lomb Oligonucleotide Therapeutics Product
Table 63. Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Bausch & Lomb Recent Development
Table 65. Alnylam Pharmaceuticals Company Detail
Table 66. Alnylam Pharmaceuticals Business Overview
Table 67. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product
Table 68. Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Alnylam Pharmaceuticals Recent Development
Table 70. Dynavax Technologies Company Detail
Table 71. Dynavax Technologies Business Overview
Table 72. Dynavax Technologies Oligonucleotide Therapeutics Product
Table 73. Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Dynavax Technologies Recent Development
Table 75. Kastle therapeutics Company Detail
Table 76. Kastle therapeutics Business Overview
Table 77. Kastle therapeutics Oligonucleotide Therapeutics Product
Table 78. Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Kastle therapeutics Recent Development
Table 80. Akcea Therapeutics Company Detail
Table 81. Akcea Therapeutics Business Overview
Table 82. Akcea Therapeutics Oligonucleotide Therapeutics Product
Table 83. Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Akcea Therapeutics Recent Development
Table 85. Biogen Company Information
Table 86. Biogen Business Overview
Table 87. Biogen Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 88. Biogen Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 89. Biogen Recent Development
Table 90. Sarepta Therapeutics Company Information
Table 91. Sarepta Therapeutics Business Overview
Table 92. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 94. Sarepta Therapeutics Recent Development
Table 95. Jazz Pharmaceuticals Company Information
Table 96. Jazz Pharmaceuticals Business Overview
Table 97. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 98. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 99. Jazz Pharmaceuticals Recent Development
Table 100. Bausch & Lomb Company Information
Table 101. Bausch & Lomb Business Overview
Table 102. Bausch & Lomb Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 103. Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 104. Bausch & Lomb Recent Development
Table 105. Alnylam Pharmaceuticals Company Information
Table 106. Alnylam Pharmaceuticals Business Overview
Table 107. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 108. Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 109. Alnylam Pharmaceuticals Recent Development
Table 110. Dynavax Technologies Company Information
Table 111. Dynavax Technologies Business Overview
Table 112. Dynavax Technologies Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 113. Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 114. Dynavax Technologies Recent Development
Table 115. Kastle therapeutics Company Information
Table 116. Kastle therapeutics Business Overview
Table 117. Kastle therapeutics Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 118. Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 119. Kastle therapeutics Recent Development
Table 120. Akcea Therapeutics Company Information
Table 121. Akcea Therapeutics Business Overview
Table 122. Akcea Therapeutics Oligonucleotide Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million)
Table 123. Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 124. Akcea Therapeutics Recent Development
Table 125. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Oligonucleotide Therapeutics Product Picture
Figure 5. Global Oligonucleotide Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Oligonucleotide Therapeutics Market Share by Type: 2022 VS 2029
Figure 7. Antisense Oligonucleotide Product Picture
Figure 8. Aptamer Product Picture
Figure 9. Other Product Picture
Figure 10. Global Oligonucleotide Therapeutics Market Size by Application (2023-2029) & (US$ Million)
Figure 11. Global Oligonucleotide Therapeutics Market Share by Application: 2022 VS 2029
Figure 12. Neuromuscular Diseases Product Picture
Figure 13. ATTR Product Picture
Figure 14. Hepatic VOD Product Picture
Figure 15. Other Product Picture
Figure 16. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Oligonucleotide Therapeutics Market Share by Region: 2022 VS 2029
Figure 19. Global Oligonucleotide Therapeutics Market Share by Players in 2022
Figure 20. Global Oligonucleotide Therapeutics Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Oligonucleotide Therapeutics Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Oligonucleotide Therapeutics Market Share by Country (2018-2029)
Figure 25. United States Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Oligonucleotide Therapeutics Market Share by Country (2018-2029)
Figure 29. Germany Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Oligonucleotide Therapeutics Market Share by Country (2018-2029)
Figure 37. China Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Oligonucleotide Therapeutics Market Share by Country (2018-2029)
Figure 45. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2018-2029)
Figure 49. Turkey Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Oligonucleotide Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 53. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 54. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 55. Bausch & Lomb Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 56. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 57. Dynavax Technologies Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 58. Kastle therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)
Figure 59. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2018-2023)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings